| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/GAST.1997.V113.PM9322499 |
| P698 | PubMed publication ID | 9322499 |
| P2093 | author name string | Chojkier M | |
| Venkataramani A | |||
| Lyche K | |||
| Houglum K | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis | Q62019625 |
| P304 | page(s) | 1069-1073 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. | |
| P478 | volume | 113 |
| Q92827635 | A novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis |
| Q34575223 | Alcohol and hepatitis C. |
| Q38168827 | An insight into the diagnosis and pathogenesis of hepatitis C virus infection |
| Q36376477 | Antifibrotic agents for liver disease |
| Q36036857 | Antifibrotic therapy in chronic liver disease |
| Q73739654 | Antioxidant liposoluble vitamins and carotenoids in chronic hepatitis |
| Q73931129 | Antioxidant supplementation in critical illness: what do we know? |
| Q24235796 | Antioxidant supplements for liver diseases |
| Q34225721 | Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial |
| Q35585469 | Antioxidants as therapeutic agents for liver disease |
| Q35105721 | Approaches for treatment of liver fibrosis in chronic hepatitis C |
| Q36541169 | Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats |
| Q42873630 | Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus |
| Q37043515 | Bioconjugation of oligonucleotides for treating liver fibrosis |
| Q53923243 | Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. |
| Q34279897 | Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami |
| Q33370676 | Complementary treatments of chronic viral hepatitis C |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q35124679 | Current best treatment for non-alcoholic fatty liver disease |
| Q55609866 | Current concepts and management approaches in nonalcoholic fatty liver disease. |
| Q50574552 | Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. |
| Q43871989 | Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. |
| Q36478124 | Emerging therapies for liver fibrosis |
| Q36482392 | Fucoidan partly prevents CCl4-induced liver fibrosis |
| Q36921638 | Gene modulation for treating liver fibrosis |
| Q42994111 | Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. |
| Q27473285 | Hepatitis C Virus Triggers Mitochondrial Permeability Transition with Production of Reactive Oxygen Species, Leading to DNA Damage and STAT3 Activation |
| Q45325989 | Hepatitis C Virus-Associated Cancers |
| Q42994110 | Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. |
| Q36179898 | Hepatitis C virus infection and nonalcoholic steatohepatitis |
| Q35259669 | Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress |
| Q73628545 | Hyaluronate levels and markers of oxidative stress in the serum of Sudanese subjects at risk of infection with Schistosoma mansoni |
| Q40211269 | Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. |
| Q44880241 | Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index |
| Q40679375 | Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma |
| Q44071999 | Insulin resistance in chronic hepatitits C |
| Q37345868 | Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. |
| Q42995489 | Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial |
| Q45440926 | Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis |
| Q34027605 | Is there any use for nontraditional or alternative therapies in patients with chronic liver disease? |
| Q80696380 | Is vitamin E beneficial in chronic liver disease? |
| Q45411351 | Lipid peroxidation and antioxidative status in beta-thalassemia major patients with or without hepatitis C virus infection |
| Q35068035 | Liver fibrosis -- from bench to bedside |
| Q43826554 | Malondialdehyde-acetaldehyde-protein adducts increase secretion of chemokines by rat hepatic stellate cells |
| Q36852793 | Matrix metalloproteinase gene delivery for liver fibrosis |
| Q33867088 | Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas |
| Q38990123 | Melatonin reduces oxidative damage and increases survival of mice infected with Schistosoma mansoni |
| Q35209239 | Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. |
| Q77619568 | Molecular regulation of hepatic fibrogenesis |
| Q47220679 | Morin, a plant derived flavonoid, modulates the expression of peroxisome proliferator-activated receptor-γ coactivator-1α mediated by AMPK pathway in hepatic stellate cells |
| Q43710107 | N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity |
| Q27021161 | Nonalcoholic fatty liver disease: new treatments |
| Q58782777 | Nutritional issues in patients with obesity and cirrhosis |
| Q44014362 | Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. |
| Q28282680 | Oxidative stress in critical care: is antioxidant supplementation beneficial? |
| Q35033336 | Oxidative stress in viral and alcoholic hepatitis |
| Q31161488 | Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. |
| Q34387346 | Oxidative stress-related molecules and liver fibrosis |
| Q36316956 | Pathophysiological basis for antioxidant therapy in chronic liver disease |
| Q35621270 | Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis |
| Q37324402 | Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma |
| Q43780878 | Prevention of hepatic cirrhosis in rats by hydroxyl radical scavengers |
| Q26853520 | Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy |
| Q37802379 | Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities |
| Q43104809 | Reversal of liver fibrosis |
| Q38166445 | Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy |
| Q74530067 | Sex and hepatic fibrosis |
| Q44021477 | Sp1 and Sp3 transcription factors mediate malondialdehyde-induced collagen alpha 1(I) gene expression in cultured hepatic stellate cells |
| Q40891185 | Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. |
| Q46712698 | Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis |
| Q35911123 | Targeted treatments for cirrhosis |
| Q42591676 | Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. |
| Q34170449 | The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications |
| Q35571305 | The role of alpha-tocopherol in preventing disease: from epidemiology to molecular events |
| Q34554574 | The use of selected nutrition supplements and complementary and alternative medicine in liver disease |
| Q38073028 | Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies |
| Q35046541 | Treatment of hepatic fibrosis: almost there |
| Q55380468 | Treatment of nonalcoholic fatty liver disease. |
| Q37130717 | VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. |
| Q36880090 | Vitamin E in chronic liver diseases and liver fibrosis. |
| Q77909755 | Vitamin E status in patients with liver cirrhosis: normal or deficient? |
| Q33800048 | Vitamins in the treatment of chronic viral hepatitis. |
| Q50573993 | Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. |
| Q43505689 | What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C? |
| Q73534640 | [Fibrogenesis and liver transplantation] |
| Q78072923 | [Mechanisms of hepatic fibrogenesis] |
| Q74334253 | [Prognostic and therapeutic significance of liver fibrosis] |
| Q28568750 | c-Myb modulates transcription of the alpha-smooth muscle actin gene in activated hepatic stellate cells |
| Q44430575 | l-Cysteine administration prevents liver fibrosis by suppressing hepatic stellate cell proliferation and activation |
Search more.